A series of pharmaceutical compositions containing polypeptide dual
agonist compounds and pharmaceutically acceptable salts thereof, wherein same have dual
agonist effects on a human
glucagon-like
peptide-1 (GLP-1)
receptor and a
human blood glucose-dependent insulinotropic polypeptide (GIP)
receptor, and can be used for treating non-
insulin-dependent diabetes,
insulin-dependent diabetes,
obesity and other related diseases.